- Home
- ETV vs AMLX Comparison
ETV vs AMLX Comparison
Compare ETV & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ETV
Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | ETV | AMLX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | 136 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ETV | AMLX |
|---|---|---|
| Price | $15.22 | $17.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $21.56 |
| AVG Volume (30 Days) | 167.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $13.13 | $7.48 |
| 52 Week High | $15.20 | $19.15 |
Technical Indicators
Market Signals| Indicator | ETV | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 61.15 |
| Support Level | $14.18 | $12.17 |
| Resistance Level | N/A | $18.88 |
| Average True Range (ATR) | 0.20 | 1.04 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 95.97 | 62.35 |
Price Performance
Historical ComparisonAbout ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.